The closure of Bristol Myers Squibb’s viral vector production facility in Libertyville, Illinois, signifies a strategic move to consolidate cell therapy manufacturing operations. This shift to the Devens, Massachusetts facility reflects a cost-effective and scalable manufacturing approach. With a focus on internalizing vector production, the company aims to achieve significant savings through broader restructuring efforts […]
Tag: Bristol Myers
Bristol Myers Squibb, BioNTech Collaborate on Bispecific Antibody for Solid Tumors
Bristol Myers Squibb and BioNTech have announced a strategic collaboration to co-develop and co-commercialize BNT327, an investigational bispecific antibody for numerous solid tumor types. This ground-breaking partnership aims to leverage BioNTech’s innovative approach to expedite clinical trials, reduce time to market, and explore additional potential indications. Coupled with Bristol Myers Squibb’s renowned expertise in delivering […]
